We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+52.39%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$498M
AUM Growth
+$154M
Cap. Flow
+$62.8M
Cap. Flow %
12.62%
Top 10 Hldgs %
81.5%
Holding
55
New
24
Increased
13
Reduced
1
Closed
6

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.2M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$11.6M
3
MRK icon
Merck
MRK
+$6.16M
4
IRON icon
Disc Medicine
IRON
+$5.64M
5
CYTK icon
Cytokinetics
CYTK
+$4.44M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$3.54M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.79M
3
WAT icon
Waters Corp
WAT
+$937K
4
TYRA icon
Tyra Biosciences
TYRA
+$142K

Sector Composition

Rank Sector Weight
1 Healthcare 81.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
PUT
Eli Lilly
LLY
$1.07T
$89.5M 17.98%
115,000
+75,000
+188% +$53.4M
NVO
2
Novo Nordisk
NVO
$216B
$88.8M 17.85%
691,743
-29,764
-4% -$3.54M
LLY icon
3
Eli Lilly
LLY
$1.07T
$72M 14.48%
92,593
– –
MRK icon
4
Merck
MRK
$324B
$50M 10.06%
379,200
+50,000
+15% +$6.16M
VKTX icon
5
Viking Therapeutics
VKTX
$4.04B
$35.6M 7.15%
433,580
+50,000
+13% +$2.22M
ABBV icon
6
AbbVie
ABBV
$458B
$16.5M 3.32%
90,821
– –
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.5M 2.92%
210,096
+168,496
+405% +$11.6M
ARGX icon
8
argenx
ARGX
$57.4B
$13.5M 2.71%
34,238
– –
AZN icon
9
AstraZeneca
AZN
$263B
$12.9M 2.6%
95,376
– –
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$121B
$12.1M 2.43%
+28,900
New +$12.2M
AXSM icon
11
Axsome Therapeutics
AXSM
$12.4B
$7.01M 1.41%
87,848
– –
OCUL icon
12
Ocular Therapeutix
OCUL
$1.86B
$6.59M 1.33%
724,685
+284,685
+65% +$2.02M
CYTK icon
13
Cytokinetics
CYTK
$11B
$6.28M 1.26%
89,525
+57,412
+179% +$4.44M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.7B
$6.21M 1.25%
45,000
– –
IRON icon
15
Disc Medicine
IRON
$2.83B
$5.42M 1.09%
+87,040
New +$5.64M
PCVX icon
16
Vaxcyte
PCVX
$7.89B
$5.21M 1.05%
76,255
+37,700
+98% +$2.61M
APGE icon
17
Apogee Therapeutics
APGE
$10.2B
$4.09M 0.82%
61,590
+51,209
+493% +$2.24M
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.86B
$4.01M 0.81%
+85,765
New +$3.36M
PTGX icon
19
Protagonist Therapeutics
PTGX
$8.75B
$3.6M 0.72%
124,440
+12,100
+11% +$329K
DYN icon
20
Dyne Therapeutics
DYN
$4.04B
$3.39M 0.68%
+119,488
New +$2.7M
INSM icon
21
Insmed
INSM
$23.2B
$3.21M 0.64%
118,236
+43,300
+58% +$1.21M
SWTX
22
DELISTED
SpringWorks Therapeutics
SWTX
$2.65M 0.53%
+53,930
New +$2.49M
ASND icon
23
Ascendis Pharma A/S
ASND
$16.7B
$2.4M 0.48%
+15,894
New +$2.27M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.41B
$2.3M 0.46%
+52,492
New +$2.26M
MRUS
25
DELISTED
Merus
MRUS
$2.26M 0.45%
+50,171
New +$2.03M
1
2 3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Artia Global Partners held 55 positions worth $498M, up 45% from $344M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners deployed $62.8M of net new capital in Q1 2024, opening 24 new positions and adding to 13 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Novo Nordisk, an estimated $3.54M trimmed.

  • Artia Global Partners's largest Q1 2024 buy was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.
  • Artia Global Partners added most to Intra-Cellular Therapies Inc. in Q1 2024, an estimated $11.6M increase.
  • Artia Global Partners's biggest Q1 2024 reduction was Novo Nordisk, cutting an estimated $3.54M.
  • Artia Global Partners fully exited BioMarin Pharmaceuticals in Q1 2024, selling an estimated $2.79M.
  • Artia Global Partners's ten largest holdings make up 81% of its $498M portfolio in Q1 2024.
  • Artia Global Partners opened 24 new positions and closed 6 in Q1 2024.
  • Artia Global Partners's portfolio value rose 45% quarter-over-quarter to $498M.

Based on Artia Global Partners's 13F filing for Q1 2024, filed 15 May 2024.